Registro de fonte primária
Cullinan presented initial Phase 1b/2a results for velinotamig (BCMAxCD3 T cell engager) in refractory SLE showing clinical improvement in 8/9 patients, complete renal responses in 4/7 with baseline proteinuria, deep autoantibody and B-cell reductions, and a favorable safety profile with no DLTs, ICANS or Grade >=3 CRS. This is the first clinical data announcement for the asset in SLE.
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven diseases Favorable safety profile in patients with refractory SLE CAMBRIDGE, Mass., Nov. 8, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-mo